Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference

DUBLIN, Ireland, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on Thursday, September 29 at 12:30 p.m. E.T.

A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following the conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, LUMRYZ™, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:Courtney TurianoStern Investor Relations, Inc.[email protected] (212) 698-8687

Media Contact:Gabriella GreigReal Chemistry[email protected](203) 249-2688

You May Also Be Interested In

• Computer Modelling Group Announces Annual General Meeting Voting Results
• The Great Aussie Mortgage Escape Announces Free Education Service for Australians Tackling Lifestyle Debt
• Ascent Solar Technologies (NASDAQ: ASTI) Strengthens Defense & Space Strategy as NASA Results, Multi-Orbit Testing and Drone Demand Accelerate